Daiichi Sankyo links with Kitasato for vaccine R&D
This article was originally published in Scrip
Daiichi Sankyohas struck an alliance with Japan's Kitasato Institute for the R&D, manufacturing and marketing of vaccines for infectious diseases. The tie-up, with a specialised research and commercialisation unit within the institute, will cover both prophylactic and therapeutic vaccines and may extend to collaborations with third parties. Kitasato has developed recombinant technology using the AIK-C measles strain and is also the only academic institute in Japan to operate a vaccine production facility. Daiichi Sankyo has just launched Sanofi-Aventis's paediatric Haemophilus influenzae type B vaccine ActHIB in Japan.